NEW YORK, July 6 (GenomeWeb News) - Galapagos said today that its Galadeno genomics division has entered into an agreement with Novartis Pharmaceuticals UK to design cellular assays using its SilenceSelect gene knock-down platform.
Galadeno will provide technology, reagents, and support to assist Novartis researchers in validating drug targets by analyzing protein function in human primary cells. Galadeno will receive payments related to the research services and its SilenceSelect technology.
Additional financial terms were not provided.
Galapagos said that Galadeno's SilenceSelect technology can knock down more than 4,000 human proteins by producing short interfering RNA in human cells.